What are the treatment guidelines for an adult with biopsy-proven F3 (bridging) fibrosis using resmetirom?

Treatment Guidelines for F3 Fibrosis with Resmetirom

Resmetirom is FDA-approved and recommended for treatment of adults with biopsy-proven F3 fibrosis from MASH/NASH, provided they do not have cirrhosis or evidence of portal hypertension. 1, 2

Patient Eligibility Criteria

Must Meet ALL of the Following:

• Confirmed F3 fibrosis on liver biopsy (bridging fibrosis) 1
• Diagnosis of MASLD/MASH with exclusion of other liver diseases (viral hepatitis, autoimmune hepatitis, significant alcohol use, iron overload) 1
• No cirrhosis or portal hypertension - this is critical and must be verified 1
• Age ≥18 years 2

Absolute Exclusions:

You must exclude patients with:

• Any evidence of cirrhosis (F4 on prior biopsy, imaging signs of cirrhosis) 1
• Portal hypertension indicators:
  • VCTE liver stiffness >20 kPa 1
  • MRE >5 kPa 1
  • Ascites, varices, or hepatic encephalopathy history 1
  • Platelet count suggesting portal hypertension 1
• Decompensated liver disease 2
• Significant alcohol use (PeTH >200 ng/mL if measured) 1
• Active untreated thyroid disorders 3

Dosing Regimen

Weight-based dosing is mandatory: 1, 2

• <100 kg body weight: 80 mg once daily
• ≥100 kg body weight: 100 mg once daily

Administer with or without food 2. The FDA label specifically requires this weight-based approach based on pharmacokinetic data showing lower drug exposure in higher-weight patients 2.

Drug Interactions Requiring Dose Adjustment

• Do NOT use with gemfibrozil (strong CYP2C8 inhibitor) 2
• With moderate CYP2C8 inhibitors (e.g., clopidogrel): 2
  • Reduce to 60 mg daily if <100 kg
  • Reduce to 80 mg daily if ≥100 kg
• Monitor closely with statins (increased risk of early transaminase elevation) 1

Monitoring Protocol

Baseline Assessment:

• Liver enzymes (ALT, AST), total bilirubin, alkaline phosphatase 1
• Consider baseline MRI-PDFF if available (most predictive of response) 1
• Baseline liver stiffness by VCTE or MRE 1

Month 3 - Safety Monitoring ONLY:

Do NOT assess efficacy at 3 months - changes in ALT at this timepoint do not predict treatment response 1. This visit is solely to:

• Screen for hepatotoxicity (ALT, AST, bilirubin) 2
• Assess tolerability (GI symptoms: diarrhea, nausea typically occur within first 5-28 days) 1
• Discontinue if hepatotoxicity suspected: fatigue, nausea, vomiting, right upper quadrant pain, jaundice, fever, rash, or eosinophilia >5% 2

Month 6 - Early Disease Monitoring:

• Liver enzymes 1
• Optional: VCTE or MRI-PDFF (may show early response but insufficient to judge full efficacy) 1
• Continue treatment unless intolerable GI side effects 1

Month 12 and Annually - Efficacy Assessment:

Continue treatment if ANY of the following: 1

• ALT improved >20% or normalized (compared to baseline) AND accompanied by imaging improvement
• MRI-PDFF reduced by ≥30% (most predictive of histologic response, even without ALT improvement)
• Liver stiffness improved by >30% (though VCTE alone may be inadequate)

Discontinue treatment if: 1

• No response in MRI-PDFF (if obtained at baseline)

• 30% increase in liver stiffness

• Worsening of >2 noninvasive tests
• Drug intolerance

Critical caveat: Histologic improvements may occur without corresponding changes in VCTE or liver enzymes. MRI-PDFF or repeat liver biopsy should be considered before labeling patients as non-responders 1.

Safety Considerations

Common Side Effects (>5%): 1

• Diarrhea (median onset: 6-17 days, duration: 20 days)
• Nausea (median onset: 5-28 days, duration: 26-28 days)
• Constipation, abdominal pain, vomiting
• Dose-dependent (higher with 100 mg dose)
• Led to discontinuation in 8 per 100 person-years at high dose 1

Serious Adverse Event - Hepatotoxicity:

One case of drug-induced autoimmune-like hepatitis occurred in trials (ALT 58× ULN, AST 66× ULN, bilirubin 15× ULN) 2. This resolved after discontinuation. Immediately stop resmetirom if hepatotoxicity suspected and monitor until resolution 2.

Gallbladder Problems:

Gallstones and cholecystitis can occur with NASH and potentially with resmetirom 2. Discontinue if severe abdominal pain, nausea, vomiting, or fever develop 2.

Concomitant Therapy

Diet and exercise are mandatory adjuncts per FDA label 2. Real-world data show frequent concomitant GLP-1 receptor agonist use, with treatment response appearing independent of weight-loss therapy 3. Semaglutide has also gained regulatory approval for fibrotic MASH, though optimal sequencing and combination strategies remain under investigation 3, 4.

Evidence Quality

The recommendation is based on the MAESTRO-NASH phase 3 trial 5, which demonstrated that both 80 mg and 100 mg resmetirom achieved:

• MASH resolution without fibrosis worsening: 25.9-29.9% vs 9.7% placebo (P<0.001)
• ≥1 stage fibrosis improvement: 24.2-25.9% vs 14.2% placebo (P<0.001)

In the F2-F3 subset specifically (917 patients), results were consistent: MASH resolution in 25.7-29.9% vs 9.5% placebo, and fibrosis improvement in 26.5-28.9% vs 17.3% placebo 6. This led to FDA accelerated approval in March 2024 1, 7, with full approval contingent on demonstrating clinical benefit in ongoing confirmatory trials 2.

The 2024 expert panel guidelines 1 provide the most current practical guidance for patient selection and monitoring, prioritizing data from the MAESTRO-NASH trial and FDA analysis to maximize applicability to real-world practice.